774-47-0

Basic information

• Product Name: 5,6-difluoro-indoline-2,3-dione
• Synonyms: 5,6-difluoro-2,3-dihydro-1H-indole-2,3-dione;5,6-Difluoroindole-2,3-dione;5,6-Difluoroisatine;skln-0003
• CAS NO: 774-47-0
• Molecular Formula: C₈H₃F₂NO₂
• Molecular Weight: 183.1117264
• Mol File: 774-47-0.mol
• Article Data: 7

Chemical Properties

• Melting Point: 218-220℃
• Appearance: /
• Density: 1.578 g/cm³
• Refractive Index: 1.558
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 5,6-difluoro-indoline-2,3-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 5,6-difluoro-indoline-2,3-dione(774-47-0)
• EPA Substance Registry System: 5,6-difluoro-indoline-2,3-dione(774-47-0)

Safety Data

• Hazardous Substances Data: 774-47-0(Hazardous Substances Data)

Usage

General Description

5,6-difluoro-indoline-2,3-dione is a chemical compound with the molecular formula C8H4F2N2O2. It is a heterocyclic compound that contains two fluorine atoms and is derived from the structure of indole. 5,6-difluoro-indoline-2,3-dione has applications in organic synthesis and medicinal chemistry. It is known for its potential as a building block in the development of pharmaceuticals and agrochemicals due to its unique structure and reactivity. Additionally, it has been studied for its potential as a fluorescent probe in biological imaging and as a component in materials science. Its distinct properties and reactivity make it a valuable compound for various scientific and industrial applications.

InChI:InChI=1/C8H3F2NO2/c9-4-1-3-6(2-5(4)10)11-8(13)7(3)12/h1-2H,(H,11,12,13)

Upstream product

• 302-17-0 chloral hydrate 
• 3863-11-4 3,4-difluoroaniline 
• 507-40-4 tert-butylhypochlorite 
• 5466-06-8 3-mercaptopropionic acid ethyl ester 
• 370-55-8 (2E)-N-(3,4-difluorophenyl)-2-hydroxyiminoacetamide 

Downstream Products

• 1350470-29-9 (E)-6,7-difluoro-2-styrylquinoline-4-carboxylic acid 
• 1350470-30-2 (E)-6,7-difluoro-2-[2-(4-nitrophenyl)vinyl]quinoline-4-carboxylic acid 
• 1350470-31-3 (E)-6,7-difluoro-2-[2-(4-methoxyphenyl)vinyl]quinoline-4-carboxylic acid 
• 1391858-03-9 1-benzyl-5,6-difluoroindoline-2,3-dione 

Relevant articles and documents

METHOD FOR PRODUCING ISATIN COMPOUND

PROBLEM TO BE SOLVED: To provide a method for producing an isatin compound useful as raw materials for various medical and agrochemical products and dyes, in high yield, with high purity, at low cost, and by simple operation. SOLUTION: An method for producing an isatin compound includes the reaction of an isonitrosoacetanilide compound represented by formula (1) at 15-60°C with sulfuric acid of 75% or more in concentration [R is H, a halogen atom or a linear/branched/cyclic alkyl group; n is an integer of 1-4]. SELECTED DRAWING: None COPYRIGHT: (C)2018,JPOandINPIT

Utilizing Solubility differences to achieve regiocontrol in the synthesis of substituted quinoline-4-carboxylic acids

A practical method for the regiocontrolled synthesis of substituted quinoline-4-carboxylic acids is described. Solubility differences between the product quinoline regioisomers enable their facile separation, thus avoiding any challenging chromatographic purifications and allowing access to highly substituted quinoline compounds in three steps from commercially available anilines.

Indolo[2,1-biquinazoline-6,12-dione antibacterial compounds and methods of use thereof

Methods, compounds and compositions are provided form inhibiting the growth of pathogenic mycobacteria in vitro and of treatment of pathogenic mycobacterial infections in vivo using indolo[2,1-b]quinazoline-6,12-dione compounds of the formula (I): STR1 wherein A, B, C, D, E, F, G and H are independently selected from carbon and nitrogen, or A and B or C and D can be taken together to be nitrogen or sulfur, and the pharmaceutically acceptable salts thereof. The methods, compounds and compositons are particularly useful for inhibiting the growth of Mycobacterium tuberculosis, and may be used alone, or in combination with other anti-Mycobacterium tuberculosis agents, such as isoniazid, rifampin, pyrazinamide, rifabutin, streptomycin and ciprofloxacin, to provide new agents for the treatment of tuberculosis, including multidrug-resistant tuberculosis (MDRTB).